Compare Cenovus Energy Inc (CVE) vs Heron Therapeutics Inc (HRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cenovus Energy Inc vs Heron Therapeutics Inc — how do they compare? Cenovus Energy Inc trades at $31.39 (market cap $57.90B), while Heron Therapeutics Inc trades at $0.41 (market cap $68.01M). The key difference: Cenovus Energy Inc is far larger — about 851.3× Heron Therapeutics Inc's market cap, and Cenovus Energy Inc pays a 1.97% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cenovus Energy Inc for 46 Days and Heron Therapeutics Inc for 35 Days on average.
| CVE | HRTX | |
|---|---|---|
Market Cap | $57.90B | $68.01M |
Volume | 7,863,588 | 1,891,941 |
Sector | Energy | Health |
52-Week High | $33.92 | $1.49 |
52-Week Low | $15.85 | $0.27 |
Typical Hold Time | 46 Days | 35 Days |
Enterprise Value | $63.84B | $174.75M |
Dividend Yield | 1.97% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cenovus Energy (CVE) trades at $31.49, up 2.81% with bullish technical momentum. The stock shows strong fundamentals with a P/E of 12.43 and EV/EBITDA of 6.17, trading near 52-week highs. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results pending. Operating cash flow remains robust at $8.23B despite negative net cash flow in 2025. Analyst consensus is mixed with 40.7% buy ratings amid positive media coverage highlighting growth potential.
CVE presents a compelling value opportunity with attractive valuation metrics and improving profitability. The main investment thesis centers on earnings growth recovery and operational efficiency gains. Key risks include oil price volatility and execution challenges in capital expenditure management. Institutional ownership trends and recent analyst upgrades support a cautiously optimistic outlook for medium-term appreciation.
HRTX trades at $0.3582, down 8.15% today, with a bullish technical signal from moving averages but mixed earnings. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates, continuing a trend of net losses. Analyst sentiment remains strongly positive with 89% buy ratings, though Zacks issued a Strong Sell rating in July 2026.
The outlook hinges on revenue stabilization and path to profitability. Investment opportunity lies in analyst optimism and product sales growth, but risks include persistent losses, high valuation multiples, and competitive pressures in the biotechnology sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cenovus Energy Inc
Cenovus Energy is an integrated oil company, focused on creating value through the development of its oil sands assets. The company also engages in production of conventional crude oil, natural gas liquids, and natural gas in Alberta, Canada, with refining operations in the U.S. Net upstream production averaged 472 thousand barrels of oil equivalent per day in 2020, and the company estimates that it holds 6.7 billion boe of proven and probable reserves.
Read more on CVE →About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →
